Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism

Journal of Clinical Immunology

Volumn 31, Issue 4, 2011, Pages 623-631

  Ramos Cejudo, Jaime ^a   Oreja Guevara, Celia ^a,b   Aroeira, Luiz Stark ^a   De Antonio, Luis Rodriguez ^a   Chamorro, Beatriz ^a   Diez Tejedor, Exuperio ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Cytokines; Multiple sclerosis (MS); Natalizumab; Peripheral blood; Regulatory T cells; TH1

Indexed keywords

CD28 ANTIGEN; CD3 ANTIBODY; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NATALIZUMAB; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL PROLIFERATION; CYTOKINES; FEMALE; HUMANS; INTEGRIN ALPHA4BETA1; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; T-LYMPHOCYTES, REGULATORY;

EID: 80555150830     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9522-x     Document Type: Article

References (26)

1. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med.2007;356(25):2622-9. (Pubitemid 46961007)
2. Gold R et al. Expert opinion: Guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol. 2007;187 (1-2):156-8. (Pubitemid 47001540)
3. Goodin DS et al. Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology.2008;71(10):766-73.
4. Baron JL et al. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med.1993;177(1):57-68. (Pubitemid 23008085)
5. Yednock TA et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356(6364):63-6.
6. Hellwig K et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol. 2008;65 (5):656-8. (Pubitemid 351679662)
7. Saresella M et al. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J. 2008;22(10):3500-8.
8. Vandenbark AA et al. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol.2009;215(1-2):125-8.
9. Martin-Saavedra FM et al. Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol. 2008;45 (15):4008-19.
10. Namdar A et al. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): A preliminary study. J Neuroimmunol. 2010;218(1- 2):120-4.
11. Sellner J et al. Effect of interferon-beta and atorvastatin on Th1/ Th2 cytokines in multiple sclerosis. Neurochem Int. 2008;53(1- 2):17-21.
12. Krakauer M et al. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: Interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler. 2008;14(5):622-30. (Pubitemid 351954404)
13. Sega S et al. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines. Clin Neurol Neurosurg. 2004;106(3):255-8. (Pubitemid 38716157)
14. Schrempf W, Ziemssen T. Glatiramer acetate: Mechanisms of action in multiple sclerosis. Autoimmun Rev. 2007;6(7):469-75. (Pubitemid 47069973)
15. Polman CH et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005;58 (6):840-6. (Pubitemid 41746873)
16. de Andres C et al. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: An ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol.2007;182(1-2):204-11.
17. Kivisakk P et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology.2009;72(22):1922-30.
18. Stenner MP et al. Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS ONE. 2008;3(10):e3319.
19. Mellergard J et al. Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler. 2010;16(2):208-17.
20. Khademi M et al. Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis. Eur J Neurol. 2008;15 (3):309-12. (Pubitemid 351257912)
21. Dackiw AP et al. Integrin engagement induces monocyte procoagulant activity and tumor necrosis factor production via induction of tyrosine phosphorylation. J Surg Res. 1996;64 (2):210-5. (Pubitemid 26304894)
22. Yurochko AD et al. Integrins as a primary signal transduction molecule regulating monocyte immediate-early gene induction. Proc Natl Acad Sci USA. 1992;89(19):9034-8.
23. Putzki N et al. Effects of natalizumab on circulating B cells. T regulatory cells and natural killer cells. Eur Neurol. 2010;63 (5):311-7.
24. Fletcher JM et al. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol. 2009;183(11):7602-10.
25. Baecher-Allan C, Hafler DA. Suppressor T cells in human diseases. J Exp Med. 2004;200(3):273-6. (Pubitemid 39031246)
26. Valencia X, Lipsky PE. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol. 2007;3(11):619-26.